S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI is Unstoppable. Now Is The Time! (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI is Unstoppable. Now Is The Time! (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI is Unstoppable. Now Is The Time! (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI is Unstoppable. Now Is The Time! (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
NASDAQ:CERE

Cerevel Therapeutics (CERE) Stock Forecast, Price & News

$33.38
+0.83 (+2.55%)
(As of 06/2/2023 08:48 PM ET)
Compare
Today's Range
$32.67
$33.44
50-Day Range
$23.55
$34.00
52-Week Range
$22.10
$41.46
Volume
354,600 shs
Average Volume
584,961 shs
Market Capitalization
$5.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.80

Cerevel Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
4.3% Upside
$34.80 Price Target
Short Interest
Bearish
6.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of Cerevel Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.83 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.70) to ($2.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.27 out of 5 stars

Medical Sector

955th out of 980 stocks

Pharmaceutical Preparations Industry

470th out of 485 stocks


CERE stock logo

About Cerevel Therapeutics (NASDAQ:CERE) Stock

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CERE Stock News Headlines

AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Cerevel Therapeutics Appoints Susan Altschuller As Its New CFO
Cerevel Therapeutics GAAP EPS of -$0.67 in-line
See More Headlines

CERE Price History

CERE Company Calendar

Last Earnings
5/03/2023
Today
6/04/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Coal & Consumable Fuels
Sector
Medical
Current Symbol
NASDAQ:CERE
CUSIP
15677310
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.80
High Stock Price Forecast
$46.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+4.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Net Income
$-351,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.75 per share

Miscellaneous

Free Float
150,089,000
Market Cap
$5.23 billion
Optionable
Not Optionable
Beta
1.47

Key Executives

  • Dr. N. Anthony Coles Jr. (Age 62)
    M.P.H., Exec. Chairman & CEO
    Comp: $1.01M
  • Mr. Abraham N. Ceesay M.B.A. (Age 44)
    Pres
    Comp: $776.64k
  • Mr. Mark Bodenrader (Age 49)
    Interim CFO, VP of Fin. & Chief Accounting Officer
    Comp: $440.89k
  • Mr. Scott M. Akamine J.D. (Age 37)
    Chief Legal Officer & Corp. Sec.
    Comp: $444.74k
  • Dr. Ramiro Sanchez M.D. (Age 61)
    Chief Medical Officer
    Comp: $716.29k
  • Dr. John J. Renger Ph.D. (Age 53)
    Chief Scientific Officer
  • Mr. Matthew Calistri
    VP of Investor Relations
  • Mr. Kenneth A. DiPietro (Age 63)
    Chief HR Officer
  • Ms. Kathleen Tregoning M.A. (Age 51)
    Chief Corp. Affairs Officer













CERE Stock - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CERE shares.
View CERE analyst ratings
or view top-rated stocks.

What is Cerevel Therapeutics' stock price forecast for 2023?

12 equities research analysts have issued 1-year price targets for Cerevel Therapeutics' stock. Their CERE share price forecasts range from $22.00 to $46.00. On average, they expect the company's stock price to reach $34.80 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for CERE
or view top-rated stocks among Wall Street analysts.

How have CERE shares performed in 2023?

Cerevel Therapeutics' stock was trading at $31.54 at the beginning of 2023. Since then, CERE shares have increased by 5.8% and is now trading at $33.38.
View the best growth stocks for 2023 here
.

Are investors shorting Cerevel Therapeutics?

Cerevel Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,720,000 shares, an increase of 5.8% from the April 30th total of 4,460,000 shares. Based on an average trading volume of 666,600 shares, the days-to-cover ratio is presently 7.1 days. Currently, 7.0% of the company's shares are short sold.
View Cerevel Therapeutics' Short Interest
.

When is Cerevel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our CERE earnings forecast
.

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its quarterly earnings data on Wednesday, May, 3rd. The biotechnology company reported ($0.67) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.67). During the same quarter last year, the company earned ($0.46) earnings per share.

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

What is Cerevel Therapeutics' stock symbol?

Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.98%), Price T Rowe Associates Inc. MD (3.06%), BlackRock Inc. (2.86%), State Street Corp (2.00%), Federated Hermes Inc. (1.23%) and Geode Capital Management LLC (0.80%). Insiders that own company stock include Abraham Ceesay, Deval L Patrick, Gabrielle Sulzberger, John Renger, N Anthony Coles and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Cerevel Therapeutics?

Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerevel Therapeutics' stock price today?

One share of CERE stock can currently be purchased for approximately $33.38.

How much money does Cerevel Therapeutics make?

Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $5.23 billion. The biotechnology company earns $-351,510,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Cerevel Therapeutics have?

The company employs 200 workers across the globe.

How can I contact Cerevel Therapeutics?

Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for the company is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at ir@cerevel.com.

This page (NASDAQ:CERE) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -